These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30703246)

  • 1. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
    Yata M; Kooistra HS; Beijerink NJ
    J Vet Intern Med; 2019 Mar; 33(2):462-470. PubMed ID: 30703246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK; Atkins CE; Eriksson A; Hess AM
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease.
    Oyama MA; Solter PF; Thorn CL; Stern JA
    J Vet Cardiol; 2017 Jun; 19(3):211-217. PubMed ID: 28478943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
    Coffman M; Guillot E; Blondel T; Garelli-Paar C; Feng S; Heartsill S; Atkins CE
    J Vet Intern Med; 2021 Jul; 35(4):1673-1687. PubMed ID: 34028078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
    Boswood A; Gordon SG; Häggström J; Vanselow M; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G; Kresken JG; Wendt R; Gaugele J; Killich M; Keller L; Simak J; Holler P; Bauer A; Küchenhof H; Glaus T
    J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease.
    Peddle GD; Singletary GE; Reynolds CA; Trafny DJ; Machen MC; Oyama MA
    J Vet Cardiol; 2012 Mar; 14(1):253-9. PubMed ID: 22364690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Newhard DK; Jung S; Winter RL; Duran SH
    J Vet Intern Med; 2018 Sep; 32(5):1555-1563. PubMed ID: 30084228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
    Galizzi A; Bagardi M; Stranieri A; Zanaboni AM; Malchiodi D; Borromeo V; Brambilla PG; Locatelli C
    BMC Vet Res; 2021 Jan; 17(1):15. PubMed ID: 33413406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ; French AT; Van Israël N; Smith SG; Swift ST; Lee AJ; Corcoran BM; Dukes-McEwan J
    J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
    Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.